問卷

TPIDB > Principal Investigator

Principal Investigator


Tri-Service General Hospital (在職)

Division of Hematology & Oncology

Division of General Surgery

Division of General Surgery

Division of Hematology & Oncology

Division of General Surgery

更新時間:2023-09-19

廖國秀
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

32Cases

2020-10-15 - 2027-09-01

Phase III

A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Participants With High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy (DESTINY-Breast05)
  • Condition/Disease

    HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast

  • Test Drug

    Trastuzumab deruxtecan (T-DXd; DS-8201a)

Participate Sites
13Sites

Recruiting13Sites

2023-06-01 - 2028-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

1 2 3 4